European stocks hit record highs after Fed holds stance



(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window)

* Strong domestic demand propels German industrial orders

* Fed committed to support economy until recovery more secure

* Astrazeneca gains despite restrictions on vaccine use

* UK's Johnson Matthey jumps on upbeat forecast

By Shreyashi Sanyal

April 8 (Reuters) - European stocks hit record highs on Thursday as optimism grew around a global stimulus-fuelled economic rebound after the U.S. Federal Reserve signalled it was in no hurry to tighten its monetary policy.

The pan-European STOXX 600 index .STOXX rose 0.6%, adding to gains notched earlier this week when the index erased all of its pandemic-driven losses.

Fed officials remain wary about the ongoing risks of the coronavirus pandemic and are committed to bolstering the economy until its recovery is more secure, minutes of the central bank's latest policy meeting released on Wednesday showed.

"A dovish set of meeting minutes from the Federal Reserve has further reassured investors that Jay Powell and the gang won't be turning off the stimulus taps any time soon," Connor Campbell, an analyst at Spredex, wrote in a morning note.

European Central Bank policymakers at their meeting last month debated a smaller increase in bond purchases and agreed to front-load the buying this quarter on condition it could be cut later if conditions allow, the accounts of their meeting showed.

Data showed German industrial orders rose for the second month in a row in February, driven by strong domestic demand - a further sign that manufacturers are set to cushion a pandemic-related drop in overall output in the first quarter.

European economies are holding up well despite a third wave of the pandemic, according to Mark Haefele, chief investment officer of global wealth management at UBS.

"With more vaccines becoming available from Q2, which should allow a sustainable reopening, we continue to expect a sharp rebound in the latter half of 2021, supported by high levels of savings, pent-up demand, and accommodative monetary and fiscal policy."

Investors broadly looked past news that several European countries had announced restrictions on the use of AstraZeneca's AZN.L COVID-19 vaccine in younger people, after a link was found to very rare blood clots.

The Anglo-Swedish drugmaker's shares AZN.L climbed 2.0%.

Holland-based technology investor Prosus NV PRX.AS rose slightly after it sold 2% of China's Tencent Holdings Ltd 0700.HK for $14.7 billion in the world's largest-ever block trade.

Chemicals maker Johnson Matthey JMAT.L gained 1.5% after it forecast annual profit at the top end of market expectations and said it had started a strategic review of its health business.
Reporting by Sruthi Shankar and Shreyashi Sanyal in Bengaluru; Editing by Subhranshu Sahu and Mark Heinrich

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.